Weibo Secondary Listing: HK-ADS Premium/(Discount) Views
Considering the weak sentiment on Chinese tech names, we think that Weibo pricing its H-shares at a wider discount of around 4-5% to its ADSs will...
238 Views
Pre-IPO Adlai Nortye - Insights on Pipeline and Concerns
This article mainly analyzed Adlai Nortye in terms of its important clinical-stage drug candidates, the competition pattern, commercialization...
229 Views
Pre-IPO Beijing Mabworks Biotech - MIL62 Alone Cannot Save the Situation
This article mainly analyzed Mabworks Biotech in terms of the important clinical-stage drug candidates (MIL62, MIL93, MBS301, MIL97, MIL95, MIL86,...
268 Views
Pre-IPO TransThera Sciences (Nanjing) - Insights on the Industry, the Business and the Concerns
This article mainly analyzed TransThera in terms of the industry characteristics of small molecule drug market, candidates in the pipeline (TT...
218 Views
Asymchem Labs A/H Listing Early Look - Fast Growing, Relatively Insulated
Asymchem Laboratories (002821 CH) (AL) aims to raise around US$1-1.5bn in its H-share listing in Hong Kong. The A-shares listed were listed in...
199 Views